Full-Time

Technical Services Specialist

Updated on 7/21/2026

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$115k - $130k/yr

+ Bonus

Remote in USA

Remote

Remote within the United States.

Category
Data & Analytics (1)
Required Skills
TCP/IP
JavaScript
REST APIs

Get referred to LivaNova

Find people who can refer or advise you

Requirements
  • Extensive experience in IT within a hospital environment and/or the medical device industry, including hands-on work with healthcare interfaces.
  • Deep expertise in HL7 standards (HL7 v2.x a must; HL7 v3/FHIR beneficial), including message structures, segment logic, triggers, data types, and interface troubleshooting.
  • Hands-on experience with Mirth Connect (NextGen Connect), including configuring channels, transformers, filters, scripts, destinations, database connectors, and monitoring interface performance.
  • High affinity for modern technologies with a solid understanding of current trends such as IoT, Digital Transformation, and Remote Services.
  • Working knowledge of JavaScript for interface customization and data transformation tasks.
  • Solid understanding of networking fundamentals and system integration concepts, including TCP/IP and API-based communication.
  • Demonstrated ability to quickly identify and resolve system or procedural issues, ensuring clear communication with management and affected customers.
  • Strong organizational agility, with the ability to work effectively across functions and in global, multicultural environments.
  • A customer-oriented mindset with a proactive approach to service.
  • High level of self-discipline and attention to detail.
  • Strict adherence to standard operating procedures and regulatory requirements.
  • Effective team player with the ability to work independently when required.
  • Enthusiastic, communicative personality with strong interpersonal skills and a positive team spirit.
  • Willingness to travel internationally (25%+ of total working time).
  • Excellent command of English; additional languages are considered an asset.
  • You have completed university or college studies in business informatics, computer science or a comparable specialist training course in a relevant field.
  • 3+ years of experience in Healthcare IT, HL7 Interfaces.
Responsibilities
  • Leverage HL7 expertise to define, design, and create programs, templates, and processes supporting the deployment of current and future LivaNova perfusion data‑management products.
  • Apply advanced analytical, technical, and conceptual skills to develop system solutions for healthcare interface processing.
  • Provide 2nd‑line support to global LivaNova teams and distributors’ Field Services through email and hotline channels, focusing on HL7 interface and IT‑related issues.
  • Configure channels, filters, transformers, destinations, and scripts to support multiple healthcare messaging standards (e.g., HL7 v2.x, JSON, XML).
  • Contribute to investigations of recurring technical problems and repair‑related complaints, identifying root causes and recommending solutions.
  • Communicate with and educate customer departments affected by product updates, issues, or interface changes.
  • Identify and resolve system and procedural issues promptly, ensuring timely communication to management and impacted customers.
  • Develop and maintain comprehensive technical documentation for all processes and procedures.
  • Provide support during technical trainings for Field Service Engineers when required.
  • Maintain and generate service‑related records and reports in accordance with internal standards.
  • Ensure full compliance with LivaNova policies, guidelines, and corporate values.
Desired Qualifications
  • HL7 v3/FHIR is beneficial
  • Willingness to travel internationally (25%+ of total working time)
  • Additional languages are considered an asset

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 50% Medicare reimbursement increase for epilepsy devices effective January 2026 will significantly boost revenue.
  • Essenz heart-lung machine launched in China in August 2025, driving 20% cardiopulmonary revenue growth.
  • Next-generation MRI-compatible device with rechargeable battery expected to launch in H1 2027.

What critics are saying

  • SNIA environmental liability charge of $400M in Q3 2026 will erode EPS and force R&D cuts.
  • Third-party component supply constraints for Essenz will cap placement growth at 70% by 2026, undermining revenue targets.
  • Reimbursement lag beyond six months post-FDA approval will delay $90M revenue realization and break 2026 growth guidance.

What makes LivaNova unique

  • First and only hypoglossal nerve stimulation therapy in the U.S. without complete concentric collapse contraindication.
  • PolySync algorithm achieved 84.5% response rate in obstructive sleep apnea by converting non-responders via reprogramming.
  • aura6000 System uses proximal hypoglossal nerve stimulation without requiring pre-implant DISE screening.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Mar 19th, 2026
LivaNova's aura6000 system gains FDA approval for moderate to severe obstructive sleep apnea treatment

LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.

Yahoo Finance
Feb 25th, 2026
LivaNova reports Q4 2025 results with fifth consecutive year of double-digit EPS growth

LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.

Yahoo Finance
Feb 25th, 2026
LivaNova posts third consecutive year of double-digit growth, targets 80% Essence heart-lung machine placements by 2026

LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.

PR Newswire
Feb 20th, 2026
Orrum partners with LivaNova to integrate CŌRE Insights analytics with Essenz Perfusion System

Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.

BioSpace
May 1st, 2024
Livanova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73